102878-73-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridin-4-yl-butyric acid is used as a building block in the synthesis of pharmaceutical drugs for its versatile chemical properties and potential therapeutic effects on various diseases, including cancer, diabetes, and neurodegenerative disorders.
Used in Agrochemical Industry:
P4B is utilized in the development of agrochemicals, contributing to the creation of functional materials for agricultural applications.
Used in Research and Development:
4-Pyridin-4-yl-butyric acid is employed as a valuable compound in research and development due to its unique chemical structure and pharmacological properties, which allow for the exploration of its potential in medicine and agriculture.

Upstream product

• 92501-98-9 ethyl 2-ethoxycarbonyl-4-(pyrid-4-yl)-butanoate 
• 84200-09-9 4-(3-cyanopropyl)pyridine 
• 100-43-6 4-vinylpyridine 
• 105-53-3 diethyl malonate 
• 5264-02-8 3-(4-pyridyl)-1-chloropropane 
• 2629-72-3 4-(3-Hydroxypropyl)pyridine 

Downstream Products

• 142247-38-9 4-[1-(tert-butoxycarbonyl)piperidin-4-yl]butanoic acid 
• 1027541-80-5 4-[3-({[(S)-2-Benzyloxycarbonyl-1-(2-cyclohexyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1027423-28-4 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-2-cyclohexyl-1-ethoxycarbonyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1026982-86-4 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-pentylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1026442-85-2 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-phenyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1027367-61-8 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-3,3-dimethyl-butylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1026553-33-2 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-cyclopentyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 1026493-27-5 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-cycloheptyl-ethylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

Toward the Control of the Creation of Mixed Monolayers on Glassy Carbon Surfaces by Amine Oxidation

A versatile and simple methodology for the creation of mixed monolayers on glassy carbon (GC) surfaces was developed, using an osmium-bipyridyl complex and anthraquinone as model redox probes. The work consisted in the electrochemical grafting on GC of a mixture of mono-protected diamine linkers in varying ratios which, after attachment to the surface, allowed orthogonal deprotection. After optimisation of the deprotection conditions, it was possible to remove one of the protecting groups selectively, couple a suitable osmium complex and cap the residual free amines. The removal of the second protecting group allowed the coupling of anthraquinone. The characterisation of the resulting surfaces by cyclic voltammetry showed the variation of the surface coverage of the two redox centres in relation to the initial ratio of the linking amine in solution.

Synthesis method of tirofiban hydrochloride intermediate III (by machine translation)

The invention belongs to the field, of medicine synthesis, and particularly relates to a synthesis method III of tirofiban hydrochloride intermediate. by, reduction of an intermediate I under the action of a sodium borohydride reducing system to obtain intermediate II, intermediate II under Lewis acid chloride in the presence. SOCl2 Reaction conditions of, process are mild III, and N - process operation is simple, the reaction conditions of the reaction yield, product are improved, the product purity is high, and the reaction yield is increased by, times without being subjected to column purification, to improve the clinical medication safety, of the injection using, the standard crude drug product of the pharmacopoeia standard, and is suitable, for industrial production. (by machine translation)

Nα-Imidazolylalkyl and Pyridylalkyl Derivatives of Histaprodifen: Synthesis and in Vitro Evaluation of Highly Potent Histamine H1-Receptor Agonists

A novel series of Nα-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen (6, 2-[2-(3,3-diphenylpropyl)imidazol-4-yl]ethanamine) was synthesized and evaluated as histamine H1-receptor agonists. The title compounds displayed partial agonism at contractile H1-receptors of guinea pig ileum and were at least equipotent with histamine. Agonist effects of the new derivatives were susceptible to blockade by the H1-receptor antagonist mepyramine (2-100 nM). In the imidazole series, suprahistaprodifen (51, [2-[2-(3,3-diphenylpropyl)-1H-imidazol-4-yl]ethyl]-[2-(1H-imidazol-4-yl) ethyl]amine, Nα-2-[(1H-imidazol-4-yl)ethyl]histaprodifen) showed the highest H1-receptor agonist potency ever reported in the literature (pEC50 8.26, efficacy Emax 96%). Elongation of the alkyl spacer from ethyl to butyl decreased activity from 3630% (ethyl, 51) to 163% (butyl, 53) of histamine potency. The exchange of the terminal imidazole nucleus for a pyridine ring resulted in compounds with comparably high potency. A decrease in agonist potency and efficacy was observed when the attachment of the alkyl spacer was consecutively changed from the ortho to the meta and the para position, respectively, of the pyridine ring. The pyridine series that contained a butyl chain possessed the highest potency and affinity. Nα-[4-(2-pyridyl)butyl]histaprodifen (56) emerged as a strong partial agonist, being almost equipotent with 51 (pEC50 8.16, E max 89%). Compounds 51 and 56 also showed potent partial agonism at contractile H1 receptors in guinea pig aorta and potently activated H1-receptor-mediated endothelium-dependent relaxation in the rat aorta. Compounds 51-65 displayed low to moderate affinity at H2, H3, and M3 receptors in functional models of guinea pig. Collectively, Nα-imidazolylalkyl- and Nα -pyridylalkyl-substituted histaprodifens represent a novel class of potent H1-receptor agonists. These compounds may be useful to define the (patho)physiological role of the H1-receptor and refine molecular models of H1-receptor activation.

Design of a new class of orally active fibrinogen receptor antagonists

The integrin receptor recognition sequence Arg-Gly-Asp was successfully used as a template from which to develop a series of potent, selective, orally active, peptide-based fibrinogen receptor antagonists with a long duration of action. Simple modifications centered on the Arg and Gly residues quickly led to a modified peptide (1) with significantly enhanced ability to inhibit in vitro platelet aggregation. Substitution of the guanidino group in 1 by piperidine provided 3, which showed not only a further increase in potency but also a modest degree of oral efficacy. Finally, exploration of the nature of the C-terminal amino acid, with respect to its side-chain functionality and the carboxy terminus, yielded a group of molecules that showed excellent in vitro potency for inhibiting platelet aggregation, excellent integrin selectivity, a high level of oral efficacy, and an extended duration of action.